SYBLEU Inc (CE) (SYBE) 시세

Beauty grabs off bottom.

Sybleu Inc. Describes Competitive Landscape Around Artificial Intelligence and Machine Learning in Small Molecule Drug Discovery

Sybleu acquires fifty percent stake in small molecule therapeutic compounds

Sybleu Inc. Purchases Fifty Percent Stake In Patent Protected Small Molecule Therapeutic Compounds, Anticipates Synergy With Recently In-Licensed AI/ML Engine

$SYBE Sybleu Inc. Purchases Fifty Percent Stake In Patent Protected Small Molecule Therapeutic Compounds, Anticipates Synergy With Recently In-Licensed AI/ML Engine

https://www.prnewswire.com/news-releases/sybleu-inc-purchases-fifty-percent-stake-in-patent-protected-small-molecule-therapeutic-compounds-anticipates-synergy-with-recently-in-licensed-aiml-engine-301872346.html

NEW YORK, July 11, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal and human health.

On June 30, 2023 Sybleu entered into a purchase agreement whereby Sybleu purchased from Zander Biologics, Inc. a fifty percent ownership share of certain small molecule compounds with therapeutic applications. In return, Zander received a 10% Promissory Note in the principal amount of $300,000 due and payable June 30, 2025. Zander is also entitled to receive a contingent payment of 1,000,000 Sybleu common shares in the event documentation recording this transaction is filed with the US Patent and Trademark Office on or prior to July 31, 2023.

These compounds, currently patent protected in the U.S. under patent numbers US 10,472,351 B2 and US 11,377,442 B2, can potentially be developed into therapeutic agents targeting a host of companion animal ailments including cancer and arthritis. Sybleu intends to implement its strategy of synergizing its assets by applying its in-licensed AI/ML (Artificial Intelligence/Machine Learning) engine to further develop the purchased small molecule compounds.

"By using these patent protected compounds as part of the training dataset for our in-licensed AI/ML engine, we expect to create additional compounds that are specific for activation and inhibition of the NR2F6 receptor and which are already optimized for additional properties such as toxicity and solubility," said Harry Lander, Ph.D., CSO of Sybleu. "This will potentially save years of drug screening and chemical optimization work from the drug development pathway as well as those associated costs. We believe we will be able to quickly advance the science by marrying these technologies."

"We are extremely excited to begin the process of selectively identifying, acquiring and then developing first-rate intellectual property that fits within our corporate vision," said Joseph Vaini, CEO of Sybleu.

Sybleu and Zander have agreed to jointly develop and commercialize the jointly owned intellectual property for veterinary use with each party entitled to receive a 50% share of revenues and each party responsible for a 50% share of all expenses resulting from development and commercialization.

Fyi, harry lander runs dyo bio. So in effect, he is licensing to himself as he also is cto of syblow. Self dealing loser.

Yep, been pretty ugly thus far for sure. I never thought I'd see a worse new trading OTC ticker than DPUI.....but SYBE says 'Hold My Beer'.....lol. Any time you see MM ALPS show up on one of your tickers, they are truly the kiss of death, you know there is going to be a lot of dilution.

With that said, I still think there is going to be at least one decent run here, at some point, however, it may get worse before it gets better, if it fell down into the .01 - 02 range it would be hard not to buy for me personally.....though even that could be a mistake as this has been terrible.

Syblow is tanking. Not surprising.

A nice little dip play now under $.11 cents. It won't last long, the eyes and exposure are growing today. Load up and hold. $SYBE

Interesting ticker here.

Good update and it looks like it's favorable to the market already. Up 11% and sitting at $.12 cents and we'll over its daily volume average.

$SYBE SYBLEU Inc. Announces Corporate Strategy and Public Listing

https://www.prnewswire.com/news-releases/sybleu-inc-announces-corporate-strategy-and-public-listing-301841868.html

BRONX, N.Y., June 6, 2023 /PRNewswire/ -- SYBLEU Inc. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, has begun trading on the OTC PINK markets under the symbol SYBE.

SYBLEU has developed a corporate strategy centered around acquiring intellectual property and forging strategic partnerships to advance technologies to market. The company has focused on three areas which it believes are high-growth areas in biotechnology.

First, the company is particularly interested in developing drugs for treating cancer in companion animals. Current companion animal therapies do not take advantage of the important advances that cancer therapies have enjoyed in human health. There has been a dearth of translating those advances into treating companion animals.

Second, SYBLEU is carefully examining the role of AI and machine learning in clinical diagnostics. Recognizing that the genomic revolution, when coupled with the power of artificial intelligence and machine learning, can potentially be used to predict cancer patient outcomes to a specific cancer treatment, the company's management is evaluating intellectual property in this space.

Third, advances in optics and plastics have enabled the design of disposable medical devices that, to date, have been expensive, reusable devices that must be sterilized between uses and rebuilt. The company is evaluating a technology that allows the manufacture of a disposable endoscope.

"There is so much exciting technological innovation in the biotechnology field right now," said Harry M. Lander, Ph.D., Chief Scientific Officer of SYBLEU. "It seems that a convergence of biology (e.g., genomics), computational advances (e.g., AI and machine learning) and manufacturing (e.g., 3-D printing) is occurring in several fields that is resulting in new drugs, devices and diagnostic capabilities that will have far-reaching impact on human and animal health."

"Launching SYBLEU now is very exciting," said Joe Vaini, CEO of SYBLEU. "We will examine cutting-edge technologies and perform deep due-diligence as we select which technologies to pursue. We will also ensure that SYBLEU has a top-flight management team that will complement its needs as the company grows."

Yes, Koos is out, its only Dr. Lander and Joseph G Vaini in this one.

For now the share structure here is quite good, the starting price is low and ALPS provides the ability to load a lot of shares cheaply. If this gets a promo like ONPH did, than it could be interesting with only 1.6M held at DTC.

However, on the flip side, there is also the risk ALPS could dump it into oblivion as well. Its rare in new trading OTC stocks for that to happen but it does from time to time ( ie see DPUI last year).

IDK, this is a tough one to figure out. If I were speculating I'd say there is at least one good run here before it gets decimated by convertible debt, however, I would personally not want to be holding 6 months or a year from now.

You are right! I forgot he exited stage left on this.

Just started looking into this, supposedly Koos is no longer involved here.

With that said, there are some red flags though, their initial MM is ALPS, who I would consider to be probably one of the top 3 worst MMs you want to see on a new trading ticker, as they are typically used to unload convertible debt.

The TA just updated the share structure, it looks like they were able to get a fairly large amount of shares cleared and deposited @ DTC, 1.6M, for what is essentially a shell company, I don't even see a website at first glance. Looks like they get a small amount of revenue from ONPH but I don't even know what the business is exactly, or what they are licensing....lol. Not to mention this has a large amount of convertible debt.

Started trading Tuesday, some larger trades but has not looked very good otherwise, these ones with a lot of cds can go South in a hurry.

06/01/2023--0.08952-- 22000
06/01/2023--0.09-- 20000
06/01/2023--0.109-- 2000
06/01/2023--0.11-- 2000
05/31/2023-- 0.1073-- 20000
05/31/2023-- 0.11-- 10000
05/31/2023--0.107-- 10000
05/31/2023--0.11-- 10000
05/30/2023-- 0.1073-- 180000
05/30/2023--0.11-- 5000
05/30/2023--0.11-- 80000
05/30/2023--0.11-- 10000
05/30/2023--0.11-- 90000

Well, lookee here! Another piece of public crap, er I mean stock, from the Konman Koos!

Gotta pay for that boat slip and Maserati, amirite?

UNDENIABLE!

Oh, and first!!!!!